Table 5.
Univariate and multivariate analysis for the parameters affecting grade in patients group (n = 60).
| Grade | Univariate |
#Multivariate |
||
|---|---|---|---|---|
| P | OR (95%C.I) | P | OR (95%C.I) | |
| Age (years) | 0.072 | 0.90 (0.80–1.009) | ||
| Stage$ (III) | 0.616 | 1.40 (0.11–16.45) | ||
| Affected lymph node | 0.328 | 0.950 (0.811–1.11) | ||
| Molecular type | ||||
| Luminal | 0.023* | 0.067 (0.006–0.690) | 0.027* | 0.043*(0.003–0.702) |
| Triple negative | 0.102 | 5.0 (0.728–34.3) | ||
| HER2 Positive | 0.134 | 5.50 (0.59–51.2) | ||
| Multicentric | 0.999 | – | ||
| Carcinoma in situ | 0.999 | – | ||
| ER | 0.023* | 15.0*(1.44–155.3) | 0.027* | 0.043*(0.003–0.702) |
| PR | 0.023* | 15.0*(1.44–155.3) | 0.027* | 0.043*(0.003–0.702) |
| HER2/neu | 0.850 | 1.20 (0.182–7.9) | ||
| Hb (g/dl) | 0.652 | 1.299 (0.59–2.82) | ||
| WBCs ( × 10³/μl) | 0.004* | 0.492 (0.23–1.01) | 0.061 | 0.394 (0.149–1.042) |
| Platelets ( × 10³/μl) | 0.560 | 0.999 (0.977–1.02) | ||
| CA 15–3 (IU/ml) | 0.978 | 0.984 (0.9–1.13) | ||
| EMP2 (Normal)(>0.22) | 0.097 | 0.143 (0.014–1.41) | ||
| EMP2 (Malignant) (>5.84) | 1.000 | 1.00 (0.167–5.98) | ||
| β1-Integrin (Normal) (>0.70) | 0.998 | – | ||
| β1-Integrin (Malignant) (≥10) | 0.998 | – | ||
$: Reference (I + II), OR: Odd's ratio, C.I: Confidence interval.
#: All variables with p < 0.05 was included in the multivariate.
*: Statistically significant at p ≤ 0.05.